Sign in
Not yet taking people in SpainPhase 4

Tests cabergoline for endometriosis pain and lesion size in adult women

Tests cabergoline against standard treatment in women aged 18 to 64 with endometriosis.

Key facts

Who runs it
Hospital Clinico San Carlos
Where
Madrid, SpainSee the site
Registry title
CARESS Study: Cabergoline for the Reduction of Endometriosis Symptoms and Lesion Size
Status
Not yet recruiting
Phase
Phase 4
People taking part
120 people, planned
Started
1 Sept 2025
Expected to end
31 Dec 2026
Type of study
Interventional
Record updated
17 September 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for premenopausal women aged 18 to 40 with confirmed endometriosis and pelvic pain. It tests cabergoline against standard treatment.

Age
18 to 40 years old, and premenopausal. (The registry header lists 18 to 64 years.)
Sex
The record is unclear. The sex field says male, but the criteria and summary describe women with endometriosis.
Disease stage
Endometriosis confirmed by ultrasound, magnetic resonance imaging or laparoscopy. Pelvic pain for at least 1 month, with a VAS pain score of 3 points or more.
Earlier treatment
No treatment with cabergoline in the three months before the study.

Main reasons for not taking part

  • Allergy to dopamine agonists, or serious side effects with cabergoline before
  • Severe uncontrolled other illness (ASA above III)
  • Active thromboembolic disease
  • Pregnant or breastfeeding at the start
  • Heart valve disorders, fibrotic disorders, impaired liver function, or breast cancer

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Aged between 18 and 40 years old, and premenopausal
  • Confirmed diagnosis of endometriosis by ultrasound/magnetic resonance imaging/laparoscopy
  • Pelvic pain (≥1 month) assessed using a VAS scale ≥3 points
  • No treatment with cabergoline in the three months prior to the start of the study
  • BMI between 18 and 35 kg/m²
  • No allergy to the treatments
  • Consent to participate in the study
  • Ability to speak and understand the message

Who cannot take part

  • Documented allergy to dopamine agonists or previous serious side effects with cabergoline
  • Active thromboembolic disease
  • History of heart valve disorders, history of fibrotic disorders, or impaired liver function
  • Breast Cancer
  • Severe uncontrolled comorbidities (ASA> III)
  • Pregnancy or breastfeeding at the start of the study
  • Patient unwillingness to participate in the study

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 64 years old?

Where in Spain

  • Hospital Clínico San CarlosMadrid, SpainNot yet recruiting

About the trial

What the trial wants to find out

To evaluate the efficacy of cabergoline (0.5 mg twice weekly) in reducing the size of endometriotic lesions and alleviating pelvic pain in women with confirmed endometriosis, compared with a control group receiving standard treatment (dienogest or combined contraceptives) for endometriosis.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
CARESS Study: Cabergoline for the Reduction of Endometriosis Symptoms and Lesion Size
Plain-language title
Tests cabergoline for endometriosis pain and lesion size in adult womenGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Fit questions
Built from 2025-522812-18-00, who can take part
Record updated
17 September 2025